artenimol has been researched along with pyrazolanthrone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Chen, TS; Lu, YY; Qu, JL; Wang, XP | 1 |
| Guo, M; Shao, J; Zhang, Z; Zhao, S; Zheng, S | 1 |
2 other study(ies) available for artenimol and pyrazolanthrone
| Article | Year |
|---|---|
The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells.
Topics: Anthracenes; Apoptosis; Artemisinins; bcl-2-Associated X Protein; Cell Line, Tumor; Humans; JNK Mitogen-Activated Protein Kinases; Mitochondria; Protein Kinase Inhibitors; Protein Transport | 2010 |
ROS-JNK1/2-dependent activation of autophagy is required for the induction of anti-inflammatory effect of dihydroartemisinin in liver fibrosis.
Topics: Acetylcysteine; Animals; Anthracenes; Anti-Inflammatory Agents; Antioxidants; Artemisinins; Autophagy; Carbon Tetrachloride; Gene Expression Regulation; Glutathione; Hepatic Stellate Cells; Humans; Liver; Liver Cirrhosis; Male; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Small Interfering | 2016 |